Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

The Top 5 Biosimilar Articles for the Week of July 24

July 28th 2023

By Justina Petrullo

Here are the top 5 biosimilar articles for the week of July 24, 2023.

Reference Bevacizumab and Proposed Biosimilar Show High Similarity

July 27th 2023

By Justina Petrullo

Reference bevacizumab and proposed biosimilar (BAT1706) demonstrate high similarity to each other.

Biosimilar Business News Recap: 3 Biosimilar Application Submissions; Roche Sues Biogen

July 26th 2023

By Skylar Jeremias

Formycon and Celltrion announced the FDA submissions for their aflibercept biosimilars; the European Medicines Agency accepted a marketing authorization application for an ustekinumab biosimilar; and Roche filed suit against Biogen over a tocilizumab biosimilar.

Existing FDA-Approved Biosimilars

July 25th 2023

Jonathan Kay, MD, provides an overview of the existing FDA-approved biosimilars for adalimumab.

AAM White Paper Breaks Down Drug Shortage Crisis: Causes and Solutions

July 25th 2023

By Skylar Jeremias

The Association for Accessible Medicines (AAM) published a white paper on the impact that ongoing drug shortages have had on the generic and biosimilar industries as well as possible solutions stakeholders can put into action.

Challenges Payers Face With Biosimilars

July 25th 2023

Kimberly C. Chen DO, MSHLM, and Maia Kayal, MD, MS, review the challenges related to biosimilars from the payer perspective and strategies payers may employ to help improve the uptake of biosimilars.

BioRationality: US Senate Reignites the Push for Biosimilars to Become Interchangeable

July 24th 2023

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, details his efforts to encourage congressional leaders to draft legislation that would remove interchangeability requirements and animal toxicology studies for biosimilars.

The Top 3 Policy Initiatives That Could Impact the US Biosimilar Market

July 23rd 2023

By Skylar Jeremias

Julie Reed, MS, executive director of the Biosimilars Forum, takes a look at the 3 policy initiatives that could have the greatest ramifications for the US biosimilars industry.

The Top 5 Biosimilar Articles for the Week of July 17

July 21st 2023

By Justina Petrullo

Here are the top 5 biosimilar articles for the week of July 17, 2023.

Challenges Associated With Biosimilars

July 20th 2023

Jonathan Kay, MD, discusses challenges that patients may experience related to biosimilars for inflammatory conditions.